French Pharmaceuticals & Biotech Top Stock Picks from Analysts

Nanobiotix

Market Cap: €1.6b

Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

Inventiva

Market Cap: €677.0m

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.

Valneva

Market Cap: €423.3m

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

Cellectis

Market Cap: €177.9m

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

Innate Pharma

Market Cap: €147.9m

Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

Sensorion

Market Cap: €120.7m

A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.

Adocia

Market Cap: €82.8m

A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.

OSE Immunotherapeutics

Market Cap: €74.0m

A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.

ABIONYX Pharma

Market Cap: €72.0m

A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.

AB Science

Market Cap: €66.9m

A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.

MaaT Pharma

Market Cap: €47.7m

A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.

THX Pharma Société Anonyme

Market Cap: €43.5m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

Nicox

Market Cap: €32.4m

Operates as an ophthalmology company in France and internationally.

GenSight Biologics

Market Cap: €18.8m

A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

Valbiotis

Market Cap: €17.6m

Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.

Advicenne

Market Cap: €15.6m

A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.